Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(6):491–495. doi: 10.1111/j.1349-7006.2004.tb03238.x

Expression of the prolactin‐indudble protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate

Wei Tian 1,2, Motoki Osawa 1,✉, Hidekazu Horiuchi 1, Yoshihiko Tomita 2
PMCID: PMC11158255  PMID: 15182429

Abstract

Prolactin‐inducible protein (PIP), also known as gross cystic disease fluid protein 15, is a predominant secretory protein in various body fluids, including saliva, milk and seminal plasma. Immunohistochemistry of this protein has been exploited as a clinical marker for breast cancer and Paget's disease. This study comparatively examined PIP expression in normal prostate tissues and in adenocarcinomas of the prostate. Quantitative real‐time RT‐PCR revealed low‐level presence (6%) of PIP mRNA in normal prostate tissue in comparison with the seminal vesicle. Indirect immunostaining with monoclonal antibody 3E7 displayed a positive sign for benign epithelium in 8 cases (29.6%) among 27 normal specimens; however, the incidence significantly increased to 56.1% (37/66) in instances involving primary prostate carcinoma tissues of different types. Quantitative RT‐PCR also demonstrated that PIP transcript levels in carcinoma regions were significantly higher than corresponding levels in benign regions. These findings conclusively showed that benign prostate epithelium expresses PIP at low levels; in contrast, PIP is over‐expressed in carcinomas of the prostate.

Abbreviations:

PIP

prolactin‐inducible protein

GCDFP15

gross cystic disease fluid protein 15

PSA

prostate‐specific antigen

GAPDH

glyceraldehyde‐3‐phosphate dehydrogenase

RT‐PCR

reverse transcription‐PCR

mAb

monoclonal antibody

EST

expressed sequence tag

References

  • 1. Haagensen DE, Mazoujian G. In: Haagensen DE, editor. Diseases of the breast. Philadelphia : WB Saunders Co; 1986. p. 474–500. [Google Scholar]
  • 2. Murphy LC, Tsuyuki D, Myal Y, Shiu RFC. Isolation and sequencing of a cDNA clone for a prolactin‐inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T‐47D. J Biol Chem 1987; 262: 15236–41. [PubMed] [Google Scholar]
  • 3. Autiero M, Abrescia P, Guardiola J. Interaction of seminal plasma proteins with cell surface antigens: presence of a CD4‐binding glycoprotein in human seminal plasma. Exp Cell Res 1991; 197: 268–71. [DOI] [PubMed] [Google Scholar]
  • 4. Caputo E, Autiero M, Mani JC, Basmociogullari S, Piatier‐Tonneau D, Guardiola J. Differential antibody reactivity and CD4 binding of the mammary tumor marker protein GCDFP‐15 from breast cyst and its counterparts from exocrine epithelia. Int J Cancer 1998; 78: 76–85. [DOI] [PubMed] [Google Scholar]
  • 5. Dumont M, Dauvois S, Simard J, Garcia T, Schachter B, Labrie F. Antagonism between estrogens and androgens on GCDFP‐15 gene expression in ZR‐75‐1 cells and correlation between GCDFP‐15 and estrogen as well as progesterone receptor expression in human breast cancer. J Steroid Biochem. 1989; 34: 397–402. [DOI] [PubMed] [Google Scholar]
  • 6. Carsol JL, Gingras S, Simard J. Synergistic action of prolactin (PRL) and androgen on PRL‐inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription‐5 and androgen receptor. Mol Endocrinol 2002; 16: 1696–710. [DOI] [PubMed] [Google Scholar]
  • 7. Gaubin M, Autiero M, Basmaciogullari S, Metivier D, Misehal Z, Culerrier R, Oudin A, Guardiola J, Piatier‐Tonneau D. Potent inhibition of CD4/TCR‐mediated T cell apoptosis by a CD4‐binding glycoprotein secreted from breast tumor and seminal vesicle cells. J Imm.unol 1999; 162: 2631–8. [PubMed] [Google Scholar]
  • 8. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein‐15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alphalactalbumin. Hum Pathol 1989; 20: 281–7. [DOI] [PubMed] [Google Scholar]
  • 9. Monteagudo C, Merino MJ, LaPorte N, Neumann RD. Value of gross cystic disease fluid protein‐15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol 1991; 22: 368–72. [DOI] [PubMed] [Google Scholar]
  • 10. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, Vary CP, Cole DJ, Watson PH. The potential role for prolactin‐inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer 1999; 81: 1002–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Osawa M, Seto Y, Yukawa N, Saito T, Takeichi S. A 20‐kDa protein in human seminal plasma that is identical to gross cystic disease fluid protein 15 and prolactin‐inducible protein. Arch Androl 1996; 36: 29–39. [DOI] [PubMed] [Google Scholar]
  • 12. Viacava P, Naccarato AG, Bevilacqua G. Spectrum of GCDFP‐15 expression in human fetal and adult normal tissues. Virchows Arch 1998; 432: 255–60. [DOI] [PubMed] [Google Scholar]
  • 13. Murphy LC, Lee‐Wing M, Goldenberg GJ, Shiu RP. Expression of the gene encoding a prolactin‐inducible protein by human breast cancers in vivo: correlation with steroid receptor status. Cancer Res 1987; 47: 4160–4. [PubMed] [Google Scholar]
  • 14. Satoh F, Umemura S, Osamura RY. Immunohistochemical analysis of GCDFP‐15 and GCDFP‐24 in mammary and non‐mammary tissue. Breast Cancer 2000; 7: 49–55. [DOI] [PubMed] [Google Scholar]
  • 15. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate‐specific antigen and gross cystic disease fluid protein‐15 are co‐expressed in androgen receptorpositive breast tumours. Br J Cancer 1998; 78: 360–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273–9. [DOI] [PubMed] [Google Scholar]
  • 17. Lundwall A, Bjartell A, Olsson AY, Malm J. Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non‐genital tissues. Mol Hum Reprod 2002; 8: 805–10. [DOI] [PubMed] [Google Scholar]
  • 18. Schenkels LC, Walgreen‐Weterings E, Oomen LC, Bolscher JG, Veerman EC, Nieuw Amerongen AV. In vivo binding of the salivary glycoprotein EP‐GP (identical to GCDFP‐15) to oral and non‐oral bacteria detection and identification of EP‐GP binding species. Biol Chem. 1997; 378: 83–8. [DOI] [PubMed] [Google Scholar]
  • 19. Bergamo P, Balestrieri M, Cammarota G, Guardiola J, Abrescia P. CD4‐mediated anchoring of the seminal antigen gp17 onto the spermatozoon surface. Hum. Imm.unol 1997; 58: 30–41. [DOI] [PubMed] [Google Scholar]
  • 20. Huang YH, Chu ST, Chen YH. Seminal vesicle autoantigen, a novel phospholipid‐binding protein secreted from luminal epithelium of mouse seminal vesicle, exhibits the ability to suppress mouse sperm motility. Biochem. J 1999; 343: 241–8. [PMC free article] [PubMed] [Google Scholar]
  • 21. Osawa M, Horiuchi H, Tian W, Kaneko M. Divergent evolution of the prolactin‐inducible protein gene and related genes in the mouse genome. Gene 2004; 325: 179–86. [DOI] [PubMed] [Google Scholar]
  • 22. Caputo E, Camarca A, Moharram R, Tornatore P, Thatcher B, Guardiola J, Martin BM. Structural study of GCDFP‐15/gpl7 in disease versus physiological conditions using a proteomic approach. Biochemistry 2003; 42: 6169–78. [DOI] [PubMed] [Google Scholar]
  • 23. Zenklusen JC, Bieche I, Lidereau R, Conti CJ. (C‐A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 1994; 91: 12155–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995; 1: 1385–9. [PubMed] [Google Scholar]
  • 25. Autiero M, Culerrier R, Bouchier C, Basmaciogullari S, Gaubin M, El Marhomy S, Blanchet P, Paradis V, Jardin A, Guardiola J, Piatier Tonneau D. Abnormal restriction pattern of PIP gene associated with human primary prostate cancers. DNA Cell Biol 1999; 18: 481–7. [DOI] [PubMed] [Google Scholar]
  • 26. Autiero M, Camarca A, Ciullo M, Debily MA, El Marhomy S, Pasquinelli R, Capasso I, D'Aiuto G, Anzisi AM, Piatier‐Tonneau D, Guardiola J. Intragenic amplification and formation of extrachromosomal small circular DNA molecules from the PIP gene on chromosome 7 in primary breast carcinomas. Int J Cancer 2002; 99: 370–7. [DOI] [PubMed] [Google Scholar]
  • 27. Ciullo M, Debily MA, Rozier L, Autiero M, Billault A, Mayau V, El Marhomy S, Guardiola J, Bernheim A, Coullin P, Piatier‐Tonneau D, Debatisse M. Initiation of the breakage‐fusion‐bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum. Mol Genet 2002; 11: 2887–94. [DOI] [PubMed] [Google Scholar]
  • 28. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J Pathol 2001; 158: 207–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401–6. [DOI] [PubMed] [Google Scholar]
  • 30. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone‐refractory prostate cancer. Cancer Res 2001; 61: 3550–5. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES